U.S. Ketamine Clinics Market Size, Share & Trends Analysis Report By Treatment (Depression, Anxiety, PTSD), By Therapy (On-site Therapy, Online Therapy), And Segment- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. ketamine clinics market size was estimated at USD 4.6 billion in 2022 and is expected to hit around USD 12.64 billion by 2032, poised to reach at a notable CAGR of 10.6% during the forecast period 2023 to 2032.

Key Takeaways:

• The depression segment held the largest market share of over 30.65% in 2022.
• The anxiety segment is anticipated to witness the fastest growth over the forecast period.
• The onsite therapy segment held the largest market share of over 52.70% in 2022.

U.S. Ketamine Clinics Market Report Scope

The increasing use of ketamine for various therapies, along with the expanding number of clinics offering ketamine treatments for mental health disorders, is expected to drive market growth. The National Alliance on Mental Illness reports that approximately 57.8 million adults in the U.S. (22.8%) have experienced mental illness, and 14.1 million adults experienced serious mental illness in 2021. The growing prevalence of mental health disorders is also anticipated to contribute to the growth. The rising awareness of mental health issues is expected to contribute to market growth. In 2022, the Substance Abuse and Mental Health Services Administration (SAMHSA) reported that approximately 19.86% of adults, nearly 50 million people, experienced some form of mental illness, with 4.91% having severe mental health conditions. The prevalence of mental illness varied by state, ranging from 16.37% in New Jersey to 26.86% in Utah. As people recognize the impact of mental health on overall well-being, the demand for effective treatments increases. Ketamine, traditionally used as an anesthetic, has shown promising results in treating treatment-resistant depression and other mental health disorders, leading to nationwide expansion of clinics.

The opioid crisis remains a major concern for public health in the United States. In 2020, the Centers for Disease Control and Prevention (CDC) reported over 93,331 drug overdose deaths. Ketamine offers an alternative to opioids for managing pain. It is a non-opioid analgesic that carries a low risk of addiction. A study published in the Journal of Pain Research in 2023 showed that ketamine infusions significantly reduced chronic pain intensity for patients with complex regional pain syndrome. This has generated interest in using ketamine for treating chronic pain, leading to the growth of ketamine clinics.

The increasing number of research on ketamine's therapeutic potential has contributed to the market growth. In 2019, the U.S. FDA approved esketamine, a nasal spray derived from ketami ne, for treating treatment-resistant depression. The approval followed a study published by Johns Hopkins University, that demonstrated the effectiveness of esketamine in patients with treatment-resistant depression. This approval has sparked more interest in the potential uses of ketamine for various mental health and pain conditions. As a result, an increasing number of clinics are offering ketamine treatments, and ongoing research is exploring its potential benefits and long-term effects.

The COVID-19 pandemic has had positive and negative effects on ketamine clinics in the U.S. Online ketamine therapy clinics had a positive impact from the pandemic, while onsite providers faced challenges. The demand for ketamine treatments increased due to higher levels of anxiety and depression during the pandemic. Many Americans experienced stress, isolation, and financial difficulties, leading to mental health issues. Ketamine has shown promising results in treating depression and anxiety, which has resulted in more people seeking it.

However, the pandemic also disrupted ketamine clinics, with many temporarily closing or reducing services in 2020 due to lockdowns and social distancing. This led to lower revenue and fewer patient visits.

Treatment Insights

The depression segment held the largest market share of over 30.65% in 2022. The growth of this segment is expected to be driven primarily by the increasing prevalence of major depressive disorder. From August 2020 to February 2021, the percentage of adults with depression and anxiety increased from 36.4% to 41.5%; according to the CDC, this growing prevalence of depression cases is anticipated to propel the segment growth.

The anxiety segment is anticipated to witness the fastest growth over the forecast period. Anxiety disorders are the most widespread mental illness in the U.S. As per data provided by the Anxiety and Depression Association of America, approximately 6.8 million adults and more than 31.9% of adolescents aged 13 to 18 years were affected by anxiety disorders in 2021. Moreover, the COVID-19 pandemic has heightened anxiety and stress levels, leading to an increased need for treatment and support for anxiety disorders, thereby driving the segment's growth.

Additionally, the market is expected to experience significant growth due to the rising number of PTSD cases in the country. For instance, the U.S. Department of Veterans Affairs reported that around 5% of adults are affected by PTSD each year, with approximately 13 million Americans experiencing the condition in 2020, as a result, the market is expected to expand further.

Therapy Insights

The onsite therapy segment held the largest market share of over 52.70% in 2022. Onsite therapy provides a controlled and supervised setting, ensuring the safety of patients and maximizing treatment results. During the therapy sessions, patients receive individualized care, monitoring, and support, which can improve the overall treatment experience and increase patient satisfaction.

This growing popularity has resulted in a significant rise in the number of ketamine clinics throughout the U.S. There are currently hundreds of these facilities across the country, and this number continues to grow yearly. This expansion reflects the growing acceptance of ketamine as a valuable form of mental health treatment, thereby driving the segment's growth.

The growth of the online therapy segment significantly impacted the market. With the rise of telehealth and remote healthcare services, the accessibility and convenience of online ketamine therapy have expanded significantly. This trend has been further accelerated by the COVID-19 pandemic, as virtual healthcare options gained prominence due to social distancing measures. As a result, the demand for online therapy has increased, contributing to the segment growth.

Key Companies & Market Share Insights

Market players employ various strategies to broaden the reach of their services and make them accessible in different locations. These strategies include introducing new services, partnerships, acquisitions, and expanding their operations. For instance, in January 2023, Field Trip launched its new Field Trip Online Therapy program, which provides an online ketamine therapy program for a variety of mental health disorders such as anxiety, depression, and PTSD. Some prominent players in the U.S. ketamine clinics market include:

• NY Ketamine Infusions
• Field Trip Health and Wellness Ltd.
• Ketamine Clinics Los Angeles
• Klarity Clinic
• Vitalitas Denver Ketamine Clinic
• Mindbloom, Inc
• Nue Life Health, PBC.
• Better U, LLC
• Innerwell
• Klarisana

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Ketamine Clinics market.

By Treatment 

• Depression
• Anxiety
• PTSD
• Others

By Therapy 

• On-Site therapy
• Online therapy